A Phase I/II Open-Label, Proof-of-Concept Study of Vamorolone in Children and Adolescents With Mild-Moderately Active Ulcerative Colitis
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Vamorolone (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors ReveraGen BioPharma
Most Recent Events
- 25 Sep 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 17 Apr 2020 New trial record